Surgery or Radiotherapy After PD-L1 Inhibitor (TQB-2450) and Chemotherapy Induction Therapy in Patients With Limited-stage Small-cell Lung Cancer
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
This is a non-randomized, open-label, single-center, phase II trial to evaluate the safety and effectiveness of surgery or radiotherapy after PD-L1 inhibitor (TQB2450) and chemotherapy induction therapy followed by maintenance therapy as first-line treatment in patients limited-stage SCLC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient shall sign the Informed Consent Form.
- •Aged 18 ≥ years.
- •Histological or cytological diagnosis of SCLC by needle biopsy, and extensive stage or limited stage (local advanced) confirmed by imageological examinations.
- •Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or
- •Life expectancy is at least 12 weeks.
- •At least 1 measurable lesion according to RECIST 1.
- •Patients with good function of other main organs (liver, kidney, blood system, etc.):
- •ANC count ≥1.5×10^9/L, platelet count ≥100×10^9/L，hemoglobin ≥90 g/L;
- •the international standard ratio of prothrombin time (INR) and prothrombin time (PT) < 1.5 times of upper limit of normal (ULN);
- •partial thromboplastin time (APTT) ≤1.5×ULN;
- •total bilirubin ≤1.5×ULN;
- •alanine aminotransferase (ALT) aspartate aminotransferase (AST) ≤2.5×ULN, or ALT and AST ≤5×ULN in the patients with liver metastatic tumor.
- •Fertile female patients must voluntarily use effective contraceptives not less than 120 days after chemotherapy or the last dose of TQB2450 (whichever is later) during the study period, and urine or serum pregnancy test results within 7 days prior to enrollment are negative.
- •Unsterilized male patients must voluntarily use effective contraception during the study period not less than 120 days after chemotherapy or the last dose of TQB2450 (whichever is later).
排除标准
- •Participants who have received any systemic anti-cancer treatment for SCLC, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment;
- •Administration of any Chinese medicine against cancer before administration of the drug;
- •Participants with cancer other than SCLC (excluding cervical carcinoma in situ, cured basal cell carcinoma, bladder epithelial tumor [including TA and tis]) within five years before the start of this study;
- •Participants with any unstable systemic disease (including active infection, uncontrolled hypertension), unstable angina pectoris, angina pectoris starting in the last three months, congestive heart failure (>= NYHA) Grade II), myocardial infarction (6 months before admission), severe arrhythmia requiring drug treatment, liver, kidney or metabolic diseases;
- •With activate or suspectable autoimmune disease, or autoimmune paracancer syndrome requiring systemic treatment;
- •Antibiotics were used to treat the infection for 4 weeks prior to the start of the trial;
- •Participants who were systemically treated with corticosteroids (prednisone or other corticosteroids >10 mg/ day) or other immunosuppressive agents within 2 weeks prior to first administration. In the absence of active autoimmune disease, inhaled or topical corticosteroids and adrenal hormone replacement therapy with a dose of less than 10 mg/ day of prednisone are permitted;
- •Participants who are allergic to the test drug or any auxiliary materials
- •Participants with active hepatitis B, hepatitis C or HIV;
- •The vaccine was administered within 4 weeks of the start of the trial;
- •Participants who have undergone major surgery or severe trauma in other systems within 2 months before the start of this trial;
- •Pleural effusion, pericardial effusion or ascites that are not clinically controlled and require pleural puncture or abdominal puncture drainage within 2 weeks before inclusion;
- •The patients have active pia meningioma, uncontrolled or untreated brain metastases.
- •Pregnant or lactating women;
- •Participants suffering from nervous system diseases or mental diseases that cannot cooperate;
- •Participated in another therapeutic clinical study
- •Other factors that researchers think it is not suitable for enrollment.
研究组 & 干预措施
LS-SCLC Surgery
Induction therapy: TQB2450 1200mg, d1+carboplatin (AUC5) , d1+ etoposide 100mg/m2, d1,d2,d3, q3w, 4 cycles.
Surgery (decided by MDT) Maintenance therapy: Etoposide,100 mg/m2 , d1-3 + Carboplatin,AUC5 (ivgtt, q3w,Two cycles) + TQB24501200mg, d1 (ivgtt, q3w, 1 Year) or progression disease, or other discontinuation criteria (intolerant toxicity, no more clinical benefit, receiving another anti-tumor regimen [except radiotherapy], withdrawal of informed consent or death).
干预措施: TQB2450 (Drug)
LS-SCLC Radiotherapy
Induction therapy: TQB2450 1200mg, d1+carboplatin (AUC5) , d1+ etoposide 100mg/m2, d1,d2,d3, q3w, 4 cycles.
Radiotherapy (decided by MDT) Maintenance therapy: Etoposide,100 mg/m2 , d1-3+Carboplatin,AUC5 (ivgtt, q3w,Two cycles)+TQB24501200mg, d1(ivgtt, q3w, 1 Year) or progression disease, or other discontinuation criteria (intolerant toxicity, no more clinical benefit, receiving another anti-tumor regimen [except radiotherapy], withdrawal of informed consent or death).
干预措施: TQB2450 (Drug)
结局指标
主要结局
Objective response rate (ORR)
时间窗: up to 16 months
It refers to the proportion of patients who have had a complete response or partial response (according to RECIST1.1) as confirmed by CT evaluation after 3 weeks in all patients who have completed the inductive/neoadjuvant therapy. Only patients with measurable lesions at baseline will be analyzed.
次要结局
- Event-free survival (EFS)(up to 60 months)
- Progression-free survival (PFS)(up to 60 months)
- Disease-free survival (DFS)(up to 60 months)
- Overall survival (OS)(up to 63 months)
- Major pathologic response (MPR)(up to 5 months)
- Safety: frequency of severe adverse events(up to 18 months)
- Health related quality of life (HRQol)(up to 12 months)
研究者
Peng Zhang
Director of science and education department
Shanghai Pulmonary Hospital, Shanghai, China